Adial Pharmaceuticals Wins Frost & Sullivan’s 2023 North American Precision Medicine for Habit Ailments Technology Innovation Management Award
Frost & Sullivan acknowledges Adial for its greatest practices in precision drugs for the habit disorders market
Adial Pharmaceuticals Wins Frost & Sullivan’s 2023 North American Precision Medication for Dependancy Diseases Technology Innovation Management Award
CHARLOTTESVILLE, Va., Oct. 18, 2023 (Globe NEWSWIRE) — Adial Prescription drugs, Inc. (NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical-stage biopharmaceutical organization concentrated on building therapies for the remedy and prevention of habit and linked issues, currently declared that it has been awarded the 2023 Very best Techniques Technologies Innovation Leadership Award in the North American precision drugs for addiction problems sector by Frost & Sullivan, an American business enterprise consulting company that gives sector investigation and analysis, development tactic consulting, and corporate education.
Frost & Sullivan’s Know-how Innovation Management Award acknowledges the organization that has introduced the finest underlying technologies for achieving amazing product or service and shopper accomplishment when driving future enterprise worth. The entire award report is out there at www.frost.com/Adial-Prescribed drugs.
“We are very pleased to be identified by Frost & Sullivan and to acquire their Technologies Innovation Leadership Award,” commented Cary Claiborne, Chief Govt Officer of Adial. “We believe that this acknowledgment further validates our progress and revolutionary method to dealing with Alcohol Use Dysfunction. Particularly, by combining our genetic examination with our guide drug prospect, Advertisement04, we imagine we can superior provide patients struggling from AUD as we can likely cut down weighty drinking times as effectively as make it possible for abstinence if wanted. We’d like to thank the Frost & Sullivan crew for this recognition.”
In the report, Lonita Lawrence Lobo, Senior Research Analyst at Frost & Sullivan, said, “The drug has been verified to be efficient in a subgroup of clients who test positive for the genetic examination, furnishing hope for sufferers who are undiagnosed and untreated for the reason that of a deficiency of confidence in this sort of remedy efforts. The remedy, hence, is innovative, distinctive, and helpful in managing habit issues and consequently supplies Adial Pharmaceuticals with a aggressive edge in the industry.”
About Frost & Sullivan
Frost & Sullivan is the Expansion Pipeline Company™. The Corporation powers their consumers to a upcoming formed by expansion. The Company’s Progress Pipeline as a Service™ presents the CEO and the CEO’s expansion group with a constant and arduous system of expansion opportunities, making sure extended-phrase achievement. To obtain beneficial results, their crew leverages about 60 decades of experience, coaching organizations of all styles and measurements throughout 6 continents with their established most effective procedures. To electric power your Advancement Pipeline upcoming, go to Frost & Sullivan at http://www.frost.com.
About Adial Prescription drugs, Inc.
Adial Prescription drugs is a clinical-stage biopharmaceutical enterprise targeted on the growth of treatment options for addictions and relevant conditions. The Company’s direct investigational new drug product or service, Ad04, is a genetically qualified, serotonin-3 receptor antagonist, therapeutic agent for the cure of Alcohol Use Dysfunction (AUD) in large drinking sufferers and was recently investigated in the Company’s ONWARD™ pivotal Period 3 clinical trial for the likely cure of AUD in topics with specified focus on genotypes (estimated to be roughly just one-third of the AUD population) identified working with the Company’s companion diagnostic genetic examination. ONWARD showed promising benefits in lowering drinking in hefty ingesting sufferers, and no overt basic safety or tolerability issues. Advertisement04 is also believed to have the potential to handle other addictive ailments such as Opioid Use Dysfunction, gambling, and being overweight. More facts is out there at www.adial.com.
Ahead Hunting Statements
This interaction has specified “forward-hunting statements” in the which means of the U.S. federal securities regulations. This kind of statements are centered upon several details and derived making use of several critical assumptions and are topic to regarded and unknown pitfalls, uncertainties and other factors that may possibly induce actual final results, performance or achievements to be materially various from any long run final results, efficiency or achievements expressed or implied by these types of forward-hunting statements. Statements preceded by, followed by or that or else incorporate the terms “believes,” “expects,” “anticipates,” “intends,” “assignments,” “estimates,” “strategies” and equivalent expressions or long term or conditional verbs such as “will,” “really should,” “would,” “could” and “could” are usually ahead-looking in mother nature and not historic facts, even though not all ahead-on the lookout statements include things like the foregoing. The forward-seeking statements incorporate statements about the Frost & Sullivan’s Technological innovation Innovation Management Award additional validating Adial’s progress and modern approach to dealing with Liquor Use Condition, Advertisement04 providing hope for clients who are undiagnosed and untreated mainly because of a deficiency of confidence in procedure attempts, the remedy providing Adial with a aggressive edge in the market place and the probable of Advert04 to treat other addictive problems this kind of as opioid use problem, gambling, and weight problems. Any ahead-seeking statements incorporated herein replicate our present-day sights, and they contain specific threats and uncertainties, which includes, amid many others, our skill to go after our regulatory method, our potential to progress ongoing partnering discussions, our ability to execute on our organization technique and deliver Ad04 to huge markets in the most price-helpful and timely manner, our potential to attain regulatory approvals for commercialization of merchandise candidates or to comply with ongoing regulatory demands, our ability to develop strategic partnership prospects and maintain collaborations, our potential to get or keep the funds or grants necessary to fund our analysis and enhancement activities, our capability to retain our vital workers or preserve our Nasdaq listing, our skill to complete clinical trials on time and achieve ideal benefits and advantages as anticipated, regulatory limitations relating to our potential to promote or commercialize our products candidates for distinct indications, acceptance of our products candidates in the marketplace and the productive growth, advertising and marketing or sale of our goods, our capacity to manage our license agreements and the ongoing servicing and development of our patent estate. These pitfalls should really not be construed as exhaustive and really should be read through jointly with the other cautionary statement included in our Yearly Report on Variety 10-K for the 12 months finished December 31, 2022, subsequent Quarterly Experiences on Variety 10-Q and latest studies on Sort 8-K filed with the Securities and Trade Commission. Any ahead-hunting assertion speaks only as of the date on which it was originally designed. We undertake no obligation to publicly update or revise any ahead-looking statement, whether or not as a result of new details, long run activities, adjusted instances or in any other case, unless of course expected by legislation.
Speak to:
Crescendo Communications, LLC
David Waldman / Alexandra Schilt
Tel: 212-671-1020
Electronic mail: adil@crescendo-ir.com
A photograph accompanying this announcement is accessible at https://www.globenewswire.com/NewsRoom/AttachmentNg/7c016f2c-0abc-4d9c-b0e6-a07942b7b8db.
